Only a few days after the expulsion of Novak Djokovic from the Australian Open, the boss of a Danish biotech made some surprising revelations to Reuters. The tennis player has acquired shares in this company which is developing an anti-Covid-19 treatment.
New twist in the Novak Djokovic saga. For several weeks, the world number 1 in tennis has been at the center of all attention. The Serbian tennis player, who refuses to be vaccinated against Covid-19, was excluded from the Australian Open and expelled from the country, after the cancellation of his visa. “I will take some time to rest and recover before making any further comments. I am very disappointed that the Court rejected my request after the Minister’s decision to cancel my visa, which means that I cannot stay in Australia and participate in the Australian Open”, reacted the 34-year-old tennis player on Sunday January 16, 2022. And to declare: “I respect the judgment of the court and I will cooperate with the relevant authorities regarding my departure from the country.”
Investment in a company developing a treatment for Covid-19
As the Covid-19 pandemic continues to spread across the world and restrictions tighten, Novak Djokovic may face further hurdles. Indeed, the tennis legend could see himself refuse participation in the next Grand Slam, Roland-Garros, in May 2022. “The vaccination pass has been adopted. As soon as the law is promulgated, it will become compulsory to enter the ERP already subject to the health pass (stadium, theater or lounge) for all spectators, practitioners, French or foreign professionals. “, indicated on Twitter the Minister Delegate for Sports, Roxana Maracineanu, Sunday January 16.
Following this incredible soap opera, the president of the QuantBioRes company made an unexpected announcement on Wednesday January 19, 2022. Interviewed by the Reuters agency, Ivan Loncarevic revealed that Novak Djokovic had bought 80% of Danish biotech shares, who develops coronavirus treatment, in June 2020. The boss of the company nevertheless refused to specify the amount of this investment. Like what, “Novax” can remain sensitive to this major subject.